Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 3/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.55 |
| ▸ | DRD4 | P21917 | 2/20 | 0.55 |
| ▸ | DRD3 | P35462 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | PRCP | P42785 | 1/20 | 0.55 |
| ▸ | EBP | Q15125 | 1/20 | 0.55 |
| ▸ | KMO | O15229 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3356779 | 0.98 | HDAC4 (0.59) | HDAC4HDAC2HDAC8DRD2SIGMAR1 | |
| SCHEMBL4962000 | 0.98 | HDAC4 (0.59) | HDAC4HDAC2HDAC8DRD2SIGMAR1 | |
| SCHEMBL5272910 | 0.98 | HDAC4 (0.59) | HDAC4HDAC2HDAC8DRD2SIGMAR1 | |
| SCHEMBL1982025 | 0.98 | HDAC4 (0.59) | HDAC4HDAC2HDAC8DRD2SIGMAR1 | |
| SCHEMBL4959143 | 0.98 | HDAC4 (0.59) | HDAC4HDAC2HDAC8DRD2SIGMAR1 | |
| SCHEMBL219530 | 0.98 | HDAC4 (0.59) | HDAC4HDAC2HDAC8DRD2SIGMAR1 | |
| SCHEMBL31123519 | 0.98 | HDAC4 (0.59) | HDAC4HDAC2HDAC8DRD2SIGMAR1 | |
| SCHEMBL4961955 | 0.98 | HDAC4 (0.59) | HDAC4HDAC2HDAC8DRD2SIGMAR1 | |
| SCHEMBL28703324 | 0.96 | HDAC4 (0.58) | HDAC4HDAC2HDAC8DRD2SIGMAR1 | |
| SCHEMBL1658753 | 0.96 | HDAC4 (0.56) | HDAC4HDAC2HDAC8DRD2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| CN-110804072-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-110790789-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-04-20 | — | — | US | disclosed |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-04-20 | — | — | US | disclosed |
| WO-2023017152-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2023-02-16 | — | — | WO | disclosed |
| US-11447511-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2022-09-20 | — | — | US | disclosed |
| EP-3572410-B1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2022-07-20 | — | — | EP | disclosed |
| US-6034069-A | 3-'N-modified 6-O-substituted erythromycin ketolide derivatives having antibacterial activity | ABBOTT LABORATORIES (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0958282-A1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | Pfizer Products Inc. (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1999016779-A1 | 3'-N-MODIFIED 6-O-SUBSTITUTED ERYTHROMYCIN KETOLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | ABBOTT LABORATORIES (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1998034919-A1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | PFIZER PRODUCTS INC. (US) | 1998-08-13 | — | — | WO | disclosed |
| EP-0344519-B1 | SUBSTITUTED 4-(QUINOLIN-2-YL-METHOXY)PHENYL-ACETIC-ACID DERIVATIVES | BAYER AG (DE) | 1993-04-14 | — | — | EP | disclosed |
| EP-0344519-A1 | Substituted 4-(quinolin-2-yl-methoxy)phenyl-acetic-acid derivatives | BAYER AG (DE) | 1989-12-06 | — | — | EP | disclosed |
| US-4692555-A | Preparation of diphenolics | ETHYL CORPORATION (US) | 1987-09-08 | — | — | US | disclosed |
| US-4680370-A | Branched polycarbonate composition from tris(hydroxyaryl)phosphorus compound | THE DOW CHEMICAL COMPANY (US) | 1987-07-14 | — | — | US | disclosed |
| US-4308180-A | TIRE TREADS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-12-29 | — | — | US | disclosed |
| US-4001183-A | 1,4-BIS(4',4'-DIHYDROXY-TRIPHENYL-METHYL)-BENZENE | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NT5C | HDAC4 3565/4885HDAC2 3972/4885HDAC8 3613/4885 |
| US-11447511-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | HDAC4 3656/4885HDAC2 3962/4885HDAC8 3783/4885 |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | HDAC4 3656/4885HDAC2 3962/4885HDAC8 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.